Yukiko Kimura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1020505/publications.pdf

Version: 2024-02-01

49 papers

2,678 citations

304368

22

h-index

243296 44 g-index

52 all docs 52 docs citations

52 times ranked 2062 citing authors

#	Article	IF	CITATIONS
1	Pediatric Rheumatology Comes of Age: Part II. Rheumatic Disease Clinics of North America, 2022, 48, xix-xx.	0.8	O
2	Translating research into practice—implementation recommendations for pediatric rheumatology; Proceedings of the childhood arthritis and rheumatology research alliance 2020 implementation science retreat. Pediatric Rheumatology, 2022, 20, 10.	0.9	2
3	The importance of rigorous methods in observational comparative effectiveness studies of rare diseases: comment on the article by Ruperto et al. Arthritis and Rheumatology, 2022, 74, 912-913.	2.9	O
4	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. Arthritis and Rheumatology, 2022, 74, 570-585.	2.9	11
5	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2022, 74, 553-569.	2.9	68
6	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. Arthritis Care and Research, 2022, 74, 505-520.	1.5	15
7	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2022, 74, 521-537.	1.5	27
8	Co-design of an Electronic Dashboard to Support the Coproduction of Care in Pediatric Rheumatic Disease: Human-Centered Design and Usability Testing. Journal of Participatory Medicine, 2022, 14, e34735.	0.7	2
9	Efficacy and Safety of Tocilizumab for Polyarticularâ€Course Juvenile Idiopathic Arthritis in the Openâ€Label Twoâ€Year Extension of a Phase III Trial. Arthritis and Rheumatology, 2021, 73, 530-541.	2.9	16
10	Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study. Arthritis and Rheumatology, 2021, 73, 1910-1920.	2.9	18
11	Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatric Rheumatology, 2021, 19, 131.	0.9	3
12	CARRA. Rheumatic Disease Clinics of North America, 2021, 47, 531-543.	0.8	3
13	Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. Arthritis and Rheumatology, 2021, 73, 1898-1909.	2.9	19
14	Pediatric Rheumatology Comes of Age. Rheumatic Disease Clinics of North America, 2021, 47, xvii-xviii.	0.8	0
15	Functional Ability and Healthâ€Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2020, 73, 1264-1274.	1.5	4
16	New Medications Are Needed for Children With Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2020, 72, 1945-1951.	2.9	28
17	Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2019, 71, 1976-1984.	2.9	8
18	Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial. Pediatric Rheumatology, 2019, 17, 57.	0.9	18

#	Article	IF	Citations
19	Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti–Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. Arthritis and Rheumatology, 2019, 71, 451-459.	2.9	36
20	Multisite Randomized Clinical Trial Evaluating an Online Self-Management Program for Adolescents With Juvenile Idiopathic Arthritis. Journal of Pediatric Psychology, 2019, 44, 363-374.	1.1	24
21	Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti–Tumor Necrosis Factor Therapy inAChildren With Polyarticular Forms of Juvenile IdiopathicÂArthritis With Clinically Inactive Disease. Arthritis and Rheumatology, 2018, 70, 1508-1518.	2.9	26
22	The Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. Arthritis and Rheumatology, 2018, 70, 669-678.	2.9	40
23	High Levels of <scp>DEK</scp> Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti–Tumor Necrosis Factor Therapy. Arthritis and Rheumatology, 2018, 70, 594-605.	2.9	11
24	Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST). Clinical Trials, 2018, 15, 268-277.	0.7	19
25	Adding patient-reported outcomes to a multisite registry to quantify quality of life and experiences of disease and treatment for youth with juvenile idiopathic arthritis. Journal of Patient-Reported Outcomes, 2018, 2, .	0.9	20
26	The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review. Clinical and Experimental Rheumatology, 2018, 36, 920-928.	0.4	8
27	Dr. Janow, et al reply. Journal of Rheumatology, 2017, 44, 960.2-960.	1.0	0
28	Pilot study comparing the Childhood Arthritis & Delate Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. Pediatric Rheumatology, 2017, 15, 23.	0.9	41
29	The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12Âmonths. Pediatric Rheumatology, 2017, 15, 30.	0.9	80
30	The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010–2013. Journal of Rheumatology, 2016, 43, 1755-1762.	1.0	41
31	Primary Sjögren Syndrome in a Child with a Neuromyelitis Optica Spectrum Disorder. Journal of Rheumatology, 2016, 43, 1260-1261.	1.0	10
32	A randomized study of local anesthesia for pain control during intra-articular corticosteroid injection in children with arthritis. Pediatric Rheumatology, 2015, 13, 36.	0.9	11
33	<i>HLA-DRB1*11</i> i>and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15970-15975.	3.3	139
34	Clinically Inactive Disease in a Cohort of Children with New-onset Polyarticular Juvenile Idiopathic Arthritis Treated with Early Aggressive Therapy: Time to Achievement, Total Duration, and Predictors. Journal of Rheumatology, 2014, 41, 1163-1170.	1.0	61
35	Adding Canakinumab to the Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Systemic Juvenile Idiopathic Arthritis: Comment on the Article by DeWitt et al. Arthritis Care and Research, 2014, 66, 1430-1431.	1.5	28
36	Extension Study of Participants from the Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2014, 41, 2459-2465.	1.0	35

#	Article	IF	CITATIONS
37	A12: The Role of Serum S100A12 Protein Levels in Disease Flare After Withdrawal of Anti-tumor Necrosis Factor Therapy in Polyarticular Forms of Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, S19-S20.	2.9	2
38	A68: The Role of Serum S100A12 Protein Levels in Maintaining Inactive Disease on Anti-tumor Necrosis Factor Therapy in Polyarticular Forms of Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, S99-S100.	2.9	2
39	A34: Seeing the Forest Through the Trees: Predictors of Inflammatory Causes of Joint Pain in New Patients. Arthritis and Rheumatology, 2014, 66, S53-S53.	2.9	2
40	Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Newâ€Onset Polyarticular Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2014, 66, 1063-1072.	1.5	101
41	2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. Arthritis and Rheumatism. 2013. 65. 2499-2512.	6.7	211
42	Longâ€Term Safety and Efficacy of Rilonacept in Patients With Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatism, 2013, 65, 2486-2496.	6.7	109
43	Pulmonary Hypertension and Other Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2013, 65, 745-752.	1.5	126
44	Enthesitis-related Arthritis Is Associated with Higher Pain Intensity and Poorer Health Status in Comparison with Other Categories of Juvenile Idiopathic Arthritis: The Childhood Arthritis and Rheumatology Research Alliance Registry. Journal of Rheumatology, 2012, 39, 2341-2351.	1.0	80
45	Disease-modifying Antirheumatic Drug Use in the Treatment of Juvenile Idiopathic Arthritis: A Cross-sectional Analysis of the CARRA Registry. Journal of Rheumatology, 2012, 39, 1867-1874.	1.0	76
46	Consensus treatment plans for newâ€onset systemic juvenile idiopathic arthritis. Arthritis Care and Research, 2012, 64, 1001-1010.	1.5	172
47	Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis and Rheumatism, 2012, 64, 2012-2021.	6.7	259
48	2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care and Research, 2011, 63, 465-482.	1.5	658
49	Pain in children with rheumatic diseases. Current Rheumatology Reports, 2006, 8, 480-488.	2.1	8